As Fstl1 deletion on myofibroblasts also had antifibrotic effects in the lung (Fig. 5d), we assessed whether 22B6 mAb administration at day 8, 11, 14, and 17 after intratracheal silica could prevent further progression of lung fibrosis (Fig. 6j). Here, FSTL1 is linked to pulmonary fibrosis.